3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myeloid, Acute
3
beta-Thalassemia
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelomonocytic, Juvenile
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Thalassemia
1
Primary Myelofibrosis
1
Neurofibromatosis 1
1
Neoplasm, Residual
1
Multiple Myeloma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Large Granular Lymphocytic
1
Leukemia
1
Influenza, Human
1
Chromosome Aberrations
1
Chromosome 7, monosomy
1
Anemia, Sickle Cell
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Azacitidine
10
Cyclophosphamide
9
venetoclax
7
fludarabine phosphate
7
fludarabine
6
Whole-Body Irradiation
6
Biopsy
6
Tacrolimus
5
Mycophenolic Acid
5
Injections
5
Decitabine
5
Busulfan
5
decitabine and cedazuridine drug combination
4
Specimen Handling
4
Peripheral Blood Stem Cell Transplantation
4
Cytarabine
4
cedazuridine
3
Stem Cell Transplantation
3
Cyclosporine
3
X-Rays
2
Vorinostat
2
Sirolimus
2
Rituximab
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Lenalidomide
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Etoposide
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myelomonocytic, Chronic
×
thymoglobulin
×
90 days
×
Clear all
NCT04888741
2026-05-05
MoTD
University of Birmingham
Phase 2
Recruiting
400 enrolled